Focusing on oncology and immunotherapy research, Protheragen has established the ImmuBridge™ multispecific antibody platform. The platform is designed to develop bispecific, trispecific and multispecific T cell engagers (TCEs) to provide pioneering solutions for tumor immunotherapy.
Combining a tumor-targeting domain with a T cell activation domain, these TCEs efficiently redirect T cells to tumor cells with high specificity, facilitating potent tumor cell killing while minimizing systemic toxicity. With an IgG-like antibody structure and a versatile target antigen (TA) design, these TCEs demonstrate wide-ranging applications in targeted cancer therapy.
Download
Our ImmuBridge™️ platform is specifically designed for developing multispecific antibodies targeting tumor antigens. We provide comprehensive research services for cancer immunotherapy to drive advancements in the field.
